Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate
Authors:
- Raf SciotRSRaf Sciot
- Maria Debiec-RychterMDMaria Debiec-Rychter
- Soren DaugaardSDSoren Daugaard
- Cyril FisherCFCyril Fisher
- Francoise CollinFCFrancoise Collin
- Martine van GlabbekeMGMartine van Glabbeke
- Jaap VerweijJVJaap Verweij
- Jean-Yves BlayJBJean-Yves Blay
- Pancras C.W. HogendoornPancras C.W. Hogendoorn
- 1 September 2008
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 44 (13) , 1855-1860
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Gastrointestinal Stromal Tumors With KIT Exon 11 Deletions Are Associated With Poor PrognosisGastroenterology, 2006
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal of Cancer, 2006
- Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide studyEuropean Journal of Cancer, 2005
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to ImatinibJournal of Clinical Oncology, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor siteLaboratory Investigation, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 2004
- Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable CourseLaboratory Investigation, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002